Bluejay Diagnostics (BJDX)
NASDAQ:BJDX
Top Page
Bluejay Diagnostics
(NASDAQ:BJDX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▲(130.77% Upside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by very weak financial performance (minimal revenue, ongoing losses, and persistent cash burn). Technicals add a mildly negative signal given the stock remains below key longer-term moving averages with negative MACD. Corporate events are a modest positive due to clinical and manufacturing progress, but they do not offset the current loss-making profile and funding/dilution overhang; valuation also offers limited support given negative earnings and no dividend.
Positive Factors
Pivotal SYMON‑II enrollment nearing completion
Near-complete enrollment in the pivotal SYMON-II study materially advances clinical validation for the Symphony IL-6 test, strengthening the regulatory pathway toward a 510(k). Successful enrollment reduces trial execution risk and shortens the timeline to potential commercial authorization and revenue realization.
Negative Factors
Minimal revenue traction
The absence of meaningful revenue across multiple years means the business lacks operating scalability and must depend on regulatory success to generate sales. Persistent no‑revenue status elevates execution risk, prolongs dependence on external financing, and makes profitability contingent on future market adoption.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal SYMON‑II enrollment nearing completion
Near-complete enrollment in the pivotal SYMON-II study materially advances clinical validation for the Symphony IL-6 test, strengthening the regulatory pathway toward a 510(k). Successful enrollment reduces trial execution risk and shortens the timeline to potential commercial authorization and revenue realization.
Read all positive factors
Bluejay Diagnostics (BJDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.73M
Dividend YieldN/A
Average Volume (3M)5.27M
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue GrowthN/A
EPS Growth97.70%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding972,215
10 Day Avg. Volume15,571,172
30 Day Avg. Volume5,266,425
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-2.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit41.99
Enterprise Value/Ebitda0.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bluejay Diagnostics Business Overview & Revenue Model
Company Description
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay pr...
How the Company Makes Money
null...
Bluejay Diagnostics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 249.04K | 0.00 |
| Gross Profit | 0.00 | -199.10K | -780.96K | 48.91K | 0.00 |
| EBITDA | -6.68M | -6.70M | -9.17M | -9.01M | -2.98M |
| Net Income | -6.85M | -7.72M | -9.95M | -9.30M | -3.73M |
Balance Sheet | |||||
| Total Assets | 7.12M | 6.66M | 4.87M | 13.52M | 21.02M |
| Cash, Cash Equivalents and Short-Term Investments | 5.16M | 4.30M | 2.21M | 10.11M | 19.05M |
| Total Debt | 120.21K | 222.25K | 352.98K | 492.62K | 0.00 |
| Total Liabilities | 1.14M | 927.92K | 1.97M | 1.98M | 637.16K |
| Stockholders Equity | 5.98M | 5.73M | 2.89M | 11.54M | 20.38M |
Cash Flow | |||||
| Free Cash Flow | -6.23M | -8.13M | -9.02M | -8.94M | -4.39M |
| Operating Cash Flow | -6.05M | -7.82M | -8.31M | -7.74M | -4.37M |
| Investing Cash Flow | -173.74K | -306.78K | -704.17K | -1.20M | -23.95K |
| Financing Cash Flow | 7.09M | 10.22M | 1.11M | 8.07K | 22.53M |
Bluejay Diagnostics Technical Analysis
Negative
0.65
Price Trends
2.27
Negative
3.04
Negative
4.98
Negative
Market Momentum
-0.08
Negative
38.06
Neutral
48.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.27, and below the 200-day MA of 4.98, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 38.06 is Neutral, neither overbought nor oversold. The STOCH value of 48.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.
Bluejay Diagnostics Risk Analysis
Bluejay Diagnostics disclosed 52 risk factors in its most recent earnings report. Bluejay Diagnostics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bluejay Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.40M | -0.28 | -191.39% | ― | ― | 76.53% | |
44 Neutral | $1.73M | -0.18 | -145.52% | ― | ― | 97.70% | |
44 Neutral | $2.68M | -0.05 | -202.20% | ― | -49.63% | 82.22% | |
42 Neutral | $20.93K | >-0.01 | ― | ― | ― | ― |
* Healthcare Sector Average
BJDX
Bluejay Diagnostics
1.78
-7.58
-80.98%
AEMD
Aethlon Medical
2.17
-26.87
-92.53%
BBLG
Bone Biologics
1.26
-2.94
-70.00%
TIVC
Tivic Health Systems
0.93
-3.36
-78.32%
DHAI
DIH Holdings US, Inc Class A
0.01
-3.76
-99.73%
Bluejay Diagnostics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial
Positive
Apr 7, 2026
On April 7, 2026, Bluejay Diagnostics, Inc. reported that it has successfully enrolled 624 patients in its ongoing SYMON-II pivotal clinical trial, which is evaluating the Symphony IL-6 test for determining patient acuity in sepsis triage and moni...
Private Placements and FinancingRegulatory Filings and Compliance
Bluejay Diagnostics Announces Insider-Funded Private Stock Placement
Positive
Mar 17, 2026
On March 14, 2024, Bluejay Diagnostics, Inc. entered into a securities purchase agreement with several board members and executives, including its president and CEO, to sell 62,500 shares of common stock at $2.00 per share in a private placement. ...
Business Operations and StrategyM&A Transactions
Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus
Neutral
Mar 16, 2026
On March 13, 2026, Bluejay Diagnostics responded to investor NorthStrive Fund II LP, which had proposed that the company consider acquiring a Phase-1-ready therapeutic program targeting refractory chronic cough to expand its clinical pipeline. Man...
Business Operations and StrategyProduct-Related Announcements
Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program
Positive
Mar 12, 2026
On March 12, 2026, Bluejay Diagnostics announced that an abstract on its Symphony IL-6 Test was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting, to be held May 18–21 in Atlanta. The work will share...
Private Placements and FinancingRegulatory Filings and ComplianceStock Split
Bluejay Diagnostics Completes Warrant Exercises, Clarifies Capital Structure
Positive
Feb 20, 2026
On February 20, 2026, Bluejay Diagnostics announced that all prefunded warrants issued in its October 2025 private placement had been fully exercised as of February 19, 2026, leaving no prefunded warrants of any class outstanding. Following these ...
Business Operations and StrategyProduct-Related Announcements
Bluejay Advances SYMON II Sepsis Study and Manufacturing
Positive
Feb 18, 2026
On February 17, 2026, Bluejay Diagnostics reported significant progress in its SYMON II multicenter IL-6 monitoring study for sepsis, having enrolled 545 patients toward a 750-patient target under approved IRB protocols. Management said the growin...
Regulatory Filings and ComplianceShareholder MeetingsStock Split
Bluejay Diagnostics Completes 1-for-4 Reverse Stock Split
Neutral
Jan 30, 2026
On June 18, 2025, stockholders of Bluejay Diagnostics approved an amendment to the company’s charter to permit a reverse stock split at ratios between 1-for-2 and 1-for-20, and on January 27, 2026 the board selected a 1-for-4 ratio, filing a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.